Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation
Drug Reduces A1C, Weight In Diabetes
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
You may also be interested in...
Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.
Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.